[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 14, 1974

Erythromycin Estolate

Author Affiliations

Redwood City, Calif

JAMA. 1974;227(2):204-205. doi:10.1001/jama.1974.03230150052031

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  The recent article in The Journal demonstrating the effectiveness of erythromycin estolate for streptococcal pharyngitis (226:531, 1973) failed to mention the hazard of using this drug. The 1973 edition of AMA Drug Evaluations on page 530 clearly states, "Erythromycin estolate, the lauryl sulfate salt of the propionyl ester of erythromycin, is the only erythromysin ester associated with hepatotoxicity. It can produce jaundice."In my estimation, this well-known fact precludes the use of the estolate under many circumstances, since there are many other erythromycin salts that are not hepatotoxic. The estolate form has no outstanding advantages over the other esters. In my judgment, the Food and Drug Administration should ban this drug.